Patent Licensing Deal Structures

The exclusive vs. nonexclusive license distinction is fundamental to patent licensing — it affects not just who can practice the patent but who has the legal standing to enforce it: EXCLUSIVE LICENSE: the licensor grants to the licensee the right to practice the patent to the exclusion of all others, INCLUDING the licensor; a truly exclusive license means even the patent owner cannot practice the patent in the licensed scope during the license term; SCOPE LIMITATIONS ON EXCLUSIVE LICENSES: a license can be exclusive within a defined scope while nonexclusive elsewhere; exclusive for field of use X (medical devices) while licensor retains right to license to other fields (consumer electronics); exclusive in territory Y (North America) while licensor retains worldwide rights; exclusive for product category Z while nonexclusive for process claims; AN EXCLUSIVE LICENSE vs. AN ASSIGNMENT: both transfer significant rights, but: assignment: transfers patent ownership (the title itself transfers); recorded at USPTO; assignee can sue without joining the original owner; exclusive license: transfers right to practice, but licensor retains ownership; if the license is so broad that it effectively conveys all substantial rights in the patent, a court may treat it as an assignment; STANDING TO SUE FOR INFRINGEMENT: EXCLUSIVE LICENSEE: generally has standing to sue infringers without joining the patent owner, because the exclusive licensee has a real economic stake in exclusivity; PATENT OWNER must be joined if the exclusive licensee lacks all substantial rights; if the license is limited in scope (field of use; territory; time), the patent owner typically must be joined; NONEXCLUSIVE LICENSEE: generally has NO standing to sue for patent infringement; rationale: a nonexclusive license only gives the right to practice — the licensor can license anyone else, so infringement doesn't deprive the nonexclusive licensee of exclusivity; the patent owner must sue; PRACTICAL EXAMPLE: if a university licenses patents exclusively to a startup for medical device applications, and a competitor infringes in that medical device field, the startup can typically sue without joining the university; if the license is only for certain product types, the university may need to be a co-plaintiff; NEGOTIATING EXCLUSIVITY: exclusive licenses are typically more expensive (upfront; milestone; royalty); negotiate the scope carefully — 'worldwide exclusive' is maximum cost; 'US nonexclusive for 1 year' is minimum cost; consider time-limited exclusivity with conversion to nonexclusive after X years or Y sales milestone.

Running royalty structures are the most common form of patent license compensation and require careful drafting of both the royalty rate and the royalty base — both have dramatic impact on the economics: RUNNING ROYALTY RATE: the percentage of sales revenue paid as a royalty; TYPICAL RATES BY INDUSTRY: consumer electronics: 0.5–3% of net selling price; semiconductor/chip: 1–5%; medical devices: 4–10% of net selling price; pharmaceuticals (composition patents): 8–20% of net sales; software (enterprise SaaS): 5–15%; telecommunications (SEPs/FRAND): calculated by top-down or comparable license methods; automotive parts: 1–4%; RATE DETERMINATION: Georgia-Pacific factors (in litigation context; 15 factors including: royalty rate in comparable licenses; nature of the license; relationship between licensor and licensee; established profitability; commercial success; utility); hypothetical negotiation benchmark (what rate would a willing licensor and willing licensee have agreed to at the time of first infringement); ROYALTY BASE ISSUES — THE SMALLEST SALABLE PATENT PRACTICING UNIT (SSPPU): patent damages and license royalties should ideally be based on the SSPPU (the smallest component that practices the patent) rather than the entire end product; SSPPU doctrine prevents royalty stacking at the product level when only one component is covered; example: modem chip patent → royalty on chip price (not phone price); but: Qualcomm; Ericsson and other SEP holders successfully license at the device level in many contexts; NET SELLING PRICE DEFINITION: critical contract drafting issue: gross selling price = list price before any deductions; net selling price = gross minus allowable deductions: (returns + credits) + (normal trade discounts) + (transportation + insurance freight) + (sales taxes + duties); careful drafting = significant $ at scale; MOST FAVORED NATION (MFN) CLAUSE: licensee protection: 'if licensor grants any third party a license under the licensed patents with a royalty rate lower than the rate paid by licensee, licensor will automatically reduce licensee's rate to that lower rate'; valuable for licensee but restricts licensor's ability to negotiate volume discounts with large companies; AUDIT RIGHTS: licensor's right to audit licensee's books to verify royalty payments; typically: annual audit right; 30–90 days notice; audit costs borne by licensor unless underpayment exceeds threshold (usually 5%); retain audit records for 3–5 years.

The payment structure of a patent license defines when and how much money flows between the parties, and different structures match different risk profiles and use cases: LUMP SUM PAYMENT: definition: a single upfront payment for all license rights for the full license term; ADVANTAGES FOR LICENSEE: certainty of total cost; no ongoing royalty accounting burden; no audit exposure; freedom to maximize product sales without sharing upside; ADVANTAGES FOR LICENSOR: immediate cash; no dependence on licensee's commercial success; no auditing burden; DISADVANTAGES: licensor gives up upside if product succeeds beyond expectations; licensee overpays if product fails; pricing a lump sum requires estimating future sales (which neither party can do reliably early in product lifecycle); WHEN LUMP SUM IS APPROPRIATE: licensor needs immediate capital; licensee has high confidence in achieving large sales volume and prefers certainty; parties have difficulty reaching agreement on royalty rate; settlement of litigation (both parties want finality); non-practicing entity (NPE) licensing programs (often prefer lump sum to avoid ongoing relationship); MILESTONE PAYMENTS: definition: payments triggered by achievement of specific events: regulatory approval (510(k); PMA; FDA drug approval); commercial launch; annual sales reaching $X; ADVANTAGES: aligns payment with value delivery; risk-sharing (licensee pays more as product succeeds); licensor receives progressively more as validation events occur; COMMON MILESTONE STRUCTURE (BIOTECH/PHARMA): upfront payment upon license execution ($100K–$5M); Phase I clinical milestone ($500K–$2M); Phase II clinical milestone ($1M–$5M); Phase III clinical milestone ($2M–$10M); FDA approval milestone ($5M–$25M); first commercial sale milestone ($1M–$5M); annual sales threshold milestones; HYBRID STRUCTURE (MOST COMMON IN COMPLEX LICENSES): combination of: upfront payment (non-refundable signing payment demonstrating commitment); milestone payments (triggered by product development achievements); running royalties (ongoing percentage of sales); annual minimums (ensuring licensor receives floor payment regardless of sales); sublicensing revenue sharing (if licensee sublicenses, licensor receives share of sublicense payments); GRANT-BACKS: licensee must grant licensor a license on any improvements the licensee makes to the licensed patents; ANTITRUST RISK: grant-backs that give licensor exclusive rights to licensee improvements may raise antitrust concerns under Section 1 Sherman Act; nonexclusive royalty-free grant-back is generally safe; exclusive grant-back may require justification.

Technology patent licensing negotiations focus on specific contract terms that have outsized economic impact — understanding these terms is essential for both licensors and licensees: KEY NEGOTIATED TERMS — FIELD OF USE: defines the permitted application scope; EXAMPLE: 'The license is limited to use in [consumer smartphone devices] and does not extend to use in [automotive systems; medical devices; industrial equipment]'; IMPACT: enables licensor to license same patent portfolio to multiple non-competing licensees in different markets; each licensee pays less (field-limited) but licensor total revenue exceeds what one exclusive licensee would pay; TERRITORY: geographic scope of the license; IMPACT: 'United States only' license means licensee cannot manufacture in China under the license; affects freedom to manufacture vs. freedom to sell; patent exhaustion doctrine (after licensed US sale, US patent rights exhausted; but foreign patents in unlicensed territories not exhausted); SUBLICENSE: right to grant sublicenses to third parties; IMPACT: a licensee with sublicense rights can build a sub-licensing business; licensor typically wants approval rights and revenue share on sublicense proceeds; common provision: 'Licensor shall receive [40%] of any sublicense fees received by Licensee'; IMPROVEMENTS AND GRANT-BACKS: REACH-THROUGH: licensor tries to capture royalties on products that use discoveries ENABLED by the licensed patents (common in upstream research tool licensing); courts have limited reach-through royalties in some contexts; MARCH-IN RIGHTS: in federally funded (Bayh-Dole) licenses: government retains right to require licensing to other parties if licensee fails to commercialize; major biotech risk if key patents arose from NIH/NSF funding; REPRESENTATIONS AND WARRANTIES: licensor represents: (a) it owns or controls the licensed patents; (b) it has not previously granted conflicting licenses; (c) to its knowledge, the patents are not subject to undisclosed encumbrances; NOTICE: licensee should require notice before licensor can terminate; cure period for payment defaults (30–60 days); WITHOUT CAUSE TERMINATION: whether licensee can terminate without cause (desirable for licensee; problematic for licensor who gave up other opportunities); DISPUTE RESOLUTION: arbitration (ICC; JAMS; AAA) vs. litigation; choice of law (Delaware; New York; California); ANTI-STACKING PROVISION: licensee's running royalty obligation is reduced if licensee must also pay royalties to third parties on the same product (prevents excessive combined royalty burden).